⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891130 | 0.88 | — | — | |
| SCHEMBL17890966 | 0.83 | — | — | |
| SCHEMBL4742746 | 0.72 | — | — | |
| SCHEMBL17891254 | 0.71 | — | — | |
| SCHEMBL8339775 | 0.66 | HTT (0.36) | — | |
| SCHEMBL17890963 | 0.65 | KMT2A (0.31) | — | |
| SCHEMBL11989420 | 0.63 | PARL (0.31) | — | |
| SCHEMBL13900968 | 0.63 | PARL (0.31) | — | |
| SCHEMBL1140513 | 0.62 | ALDH1A1 (0.33) | — | |
| SCHEMBL19446211 | 0.62 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4349363-A2 | DOSING REGIMENS | Apellis Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11903994-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3359555-B1 | DOSING REGIMENS | APELLIS PHARMACEUTICALS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11844841-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2023-03-23 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3660033-B9 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2021-12-30 | — | — | US | disclosed |
| EP-3929206-A1 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20200325175-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200282012-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3660033-A1 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200038516-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-2920201-B1 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS INC (US) | 2020-01-08 | — | — | EP | disclosed |
| US-20190194254-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2019-06-27 | — | — | US | disclosed |
| US-10035822-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170283461-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160215020-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160194359-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |